The August 2020 issue of Cell & Gene Therapy Insights, has a focus on Market access: evolving commercialization trends and strategies. PDCI Market Access’ very own Neil Palmer is featured as a guest editor and the author of the article, Under construction: roadmaps for HTA, pricing and reimbursement of cell and gene therapies.
With the number of cell and gene therapies on the rise globally, countries are beginning to build HTA and reimbursement processes to accompany these new treatments. There are numerous challenges and roadblocks in constructing these pathways and the latest issue of Cell & Gene Therapy Insights takes a closer look into these issues.
Neil’s foreword can also be viewed and downloaded here.
For inquiries related to this publication, please contact Neil Palmer, Senior Strategic Adviser & President Emeritus at PDCI Market Access.